Low‐ versus standard‐dose post‐transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation
British Journal of Haematology · 2024-03 · 204 (3) · 959-966
DOI: 10.1111/bjh.19228 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 30.11.2023. Verfasst von Shigeo Fuji und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Osaka International Cancer Institute, Osaka, Japan. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Ministry of Health, Labor, and Welfare of Japan.
Abstract (Originalsprache)
Haploidentical haematopoietic cell transplantation (haplo‐HCT) using post‐transplant cyclophosphamide (PTCY) as graft‐versus‐host disease (GVHD) prophylaxis is the standard of care for various haematological malignancies. The original PTCY dose after haplo‐HCT was 100 mg/kg, but no dose‐finding studies have been performed to identify the optimal dose. We performed a retrospective analysis to compare standard‐dose PTCY (100 mg/kg) with reduced‐dose PTCY (80 mg/kg): 969 in the standard‐dose group and 538 in the reduced‐dose group. As there was a significant difference between the two groups regarding patient and transplant characteristics, we performed propensity score (PS) matching. After PS matching, 425 patients in each group were included. The probabilities of 2‐year OS were 55.9% in the standard‐dose group and 47.0% in the reduced‐dose group ( p = 0.36). The cumulative incidences of 2‐year non‐relapse mortality were 21.3% in the standard‐dose group and 20.5% in the reduced‐dose group ( p = 0.55). There was no significant difference in the incidence of acute (grade II–IV 29.2% [95% CI, 24.9–33.6] vs. 25.3% [95% CI, 21.3–29.6]; grade III–IV 7.3% [95% CI, 5.1–10.0] vs. 6.6% [95% CI, 4.5–9.3]) or chronic GVHD. In conclusion, reduced‐ and standard‐dose PTCY were comparable in terms of major clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Hokkaido, Japan.
- Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
- Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Tōon-shi, Ehime, Japan.
- Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Chuo City, Tokyo, Japan.
- Department of Hematology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
ORCID-Profile: Shigeo Fuji, Yuho Najima, Koji Nagafuji, Ken-Ichi Matsuoka, Shuichi Ota, Yoshiko Atsuta, Kimikazu Yakushijin
Förderung
- Ministry of Health, Labor, and Welfare of Japan
Zitieren
APA
Fuji, S., Sugita, J., Najima, Y., Konishi, T., Tanaka, T., Ohigashi, H., Eto, T., Nagafuji, K., Hiramoto, N., Matsuoka, K. I., Maruyama, Y., Ota, S., Ishikawa, J., Kawakita, T., Akasaka, T., Kamimura, T., Hino, M., Fukuda, T., Atsuta, Y., & Yakushijin, K. (2024). Low‐ versus standard‐dose post‐transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. British Journal of Haematology, 204(3), 959-966. https://doi.org/10.1111/bjh.19228
Vancouver
Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, et al. Low‐ versus standard‐dose post‐transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. British Journal of Haematology. 2024;204(3):959-966. doi:10.1111/bjh.19228
BibTeX
@article{Fuji2024,
author = {Fuji, Shigeo and Sugita, Junichi and Najima, Yuho and Konishi, Tatsuya and Tanaka, Takashi and Ohigashi, Hiroyuki and Eto, Tetsuya and Nagafuji, Koji and Hiramoto, Nobuhiro and Matsuoka, Ken-Ichi and Maruyama, Yumiko and Ota, Shuichi and Ishikawa, Jun and Kawakita, Toshiro and Akasaka, Takashi and Kamimura, Tomohiko and Hino, Masayuki and Fukuda, Takahiro and Atsuta, Yoshiko and Yakushijin, Kimikazu},
title = {Low‐ versus standard‐dose post‐transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation},
journal = {British Journal of Haematology},
year = {2024},
volume = {204},
number = {3},
pages = {959--966},
doi = {10.1111/bjh.19228}
}
EUVIMED